Besides, it takes much longer time for obtaining the endocrine-resistant tumor tissues from breast cancer patients, future study will be needed to validate the roles of FDXR and CPT1A in endocrine resistance in vivo by patient-derived xenograft (PDX) models. This evidence concerns the gene FDXR and breast carcinoma.